Thompson Lester D R, Fisher Stephen I, Chu Wei Sing, Nelson Ann, Abbondanzo Susan L
Pathology Department, Southern California Permanentes Medical Group, Woodland Hills, USA.
Am J Clin Pathol. 2004 May;121(5):727-38. doi: 10.1309/PNVQ-0PQG-XHVY-6L7G.
We retrospectively analyzed 45 cases of HIV-associated Hodgkin lymphoma (HIV-HL). HIV-HL generally is a disease of young white men (mean age, 40.1 years) who acquired HIV infection by homosexual or bisexual behavior (68%), intravenous drug use (24%), and/or blood transfusion (8%). The mean interval between the diagnosis of HIV and HIV-HL was 5.2 years. Morphologic classification of nodal biopsy specimens (2001 World Health Organization criteria) included 15 mixed cellularity Hodgkin lymphomas (MCHLs), 14 nodular sclerosis Hodgkin lymphomas (NSHLs), 9 lymphocyte depleted Hodgkin lymphomas (LDHLs), and 7 classic Hodgkin lymphomas, type not further categorized. The Hodgkin-Reed-Sternberg (HRS) cells expressed positive immunoreactivity with fascin (30/30 [100%]), CD30 (35/37 [95%]), CD15 (32/36 [89%]), bcl-X(L) (25/31 [81%]), bcl-2 (15/29 [52%]), CD20 (4/34 [12%]), bcl-6 (3/28 [11%]), and Epstein-Barr virus latent membrane protein-1 (32/33 [97%]) and were nonreactive for CD138/syndecan-1. CD4 and CD8 immunostaining showed an inverted CD4/CD8 ratio (<1/20) in all cases. At diagnosis, most patients (n = 27) had high-stage disease (IV(E)) associated with an aggressive course (16% 5-year survival). LDHL behaved more aggressively than MCHL and NSHL (15% vs 40%, 5-year survival, respectively), as did disease with a sarcomatoid pattern (11% 5-year survival). Chemotherapy and radiotherapy proved efficacious in a minority of these patients.
我们回顾性分析了45例人类免疫缺陷病毒相关霍奇金淋巴瘤(HIV-HL)患者。HIV-HL通常发生于年轻白人男性(平均年龄40.1岁),他们通过同性恋或双性恋行为感染HIV(68%)、静脉吸毒(24%)和/或输血(8%)。HIV诊断与HIV-HL诊断之间的平均间隔为5.2年。根据2001年世界卫生组织标准,淋巴结活检标本的形态学分类包括15例混合细胞型霍奇金淋巴瘤(MCHL)、14例结节硬化型霍奇金淋巴瘤(NSHL)、9例淋巴细胞消减型霍奇金淋巴瘤(LDHL)和7例未进一步分类的经典型霍奇金淋巴瘤。霍奇金-里德-斯腾伯格(HRS)细胞对fascin呈阳性免疫反应(30/30 [100%])、对CD30呈阳性免疫反应(35/37 [95%])、对CD15呈阳性免疫反应(32/36 [89%])、对bcl-X(L)呈阳性免疫反应(25/31 [81%])、对bcl-2呈阳性免疫反应(15/29 [52%])、对CD20呈阳性免疫反应(4/34 [12%])、对bcl-6呈阳性免疫反应(3/28 [11%])以及对爱泼斯坦-巴尔病毒潜伏膜蛋白1呈阳性免疫反应(32/33 [97%]),且对CD138/多配体蛋白聚糖-1无反应。CD4和CD8免疫染色显示所有病例的CD4/CD8比值倒置(<1/20)。诊断时,大多数患者(n = 27)处于晚期疾病(IV(E)期),病程侵袭性强(5年生存率为16%)。LDHL的侵袭性比MCHL和NSHL更强(5年生存率分别为15%和40%),具有肉瘤样模式的疾病也是如此(5年生存率为11%)。化疗和放疗在这些患者中仅有少数有效。